Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway

Yao,Di; Wang,Suyu; Wang,Min; Lu,Weiping

doi:10.3892/mmr.2018.9393

Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway

Authors:
- Di Yao
- Suyu Wang
- Min Wang
- Weiping Lu
View Affiliations

Affiliations: Department of Endocrinology and Metabolism, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
Published online on: August 17, 2018 https://doi.org/10.3892/mmr.2018.9393
Pages: 3625-3630

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sodium‑glucose co‑transporter 2 (SGLT2) inhibitors are recently developed oral hypoglycemic agents, which act on renal proximal tubules by reducing the reabsorption of glucose and increasing the excretion of glucose in the urine. However, the mechanism underlying renoprotection has not been fully elucidated. Previous studies have indicated that the expression of high mobility group box 1 (HMGB1) increased in patients with kidney disease, and may result in renal damage through the activation of nuclear factor‑κB (NF‑κB) and an increase in receptor for advanced glycation end products (RAGE) expression. The aim of the present study was to evaluate the effects of the SGLT‑2 inhibitor dapagliflozin on cultured human proximal tubular epithelial cells (HK‑2). HK‑2 cells were grown under high glucose conditions for 48 h in the presence or absence of dapagliflozin. The markers of oxidative stress, inflammation and fibrillation levels were then detected by reverse transcription‑quantitative polymerase chain reaction and western blotting. Hyperglycemia increased the mRNA expression and protein levels of malondialdehyde (MDA), superoxide dismutase (SOD), monocyte chemoattractant protein‑1 (MCP‑1), intercellular adhesion molecule‑1 (ICAM‑1), fibronectin (FN), collagenase type 1 (COL‑1), HMGB1, RAGE and NF‑κB, and the effects could be reversed by dapagliflozin in a concentration‑dependent manner. The results of the present study suggested that HMGB1 increased the expression and secretion of markers of inflammation, oxidative stress and fibrillation, including MDA, SOD, MCP‑1, ICAM‑1, FN and COL‑1, in diabetic nephropathy. However, dapagliflozin significantly reduced the levels of inflammatory markers and postponed the progression of renal injury. It was therefore suggested this may be mediated through the inhibition of HMGB1‑RAGE-NF‑κB signaling pathway.

View Figures

View References

1	Xue R, Gui D, Zheng L, Zhai R, Wang F and Wang N: Mechanistic insight and management of diabetic nephropathy: Recent progress and future perspective. J Diabetes Res. 2017:18398092017. View Article : Google Scholar : PubMed/NCBI
2	Zhu P, Xie L, Ding HS, Gong Q, Yang J and Yang L: High mobility group box 1 and kidney diseases (Review). Int J Mol Med. 31:763–768. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kim J, Sohn E, Kim CS, Jo K and Kim JS: The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol. 33:524–529. 2011. View Article : Google Scholar : PubMed/NCBI
4	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
5	Xie J, Méndez JD, Méndez-Valenzuela V and Aguilar-Hernández MM: Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 25:2185–2197. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T, Sango K and Utsunomiya K: SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 18(pii): E10832017. View Article : Google Scholar : PubMed/NCBI
7	Komala MG, Panchapakesan U, Pollock C and Mather A: Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens. 22:113–119. 2013. View Article : Google Scholar : PubMed/NCBI
8	Moses RG, Colagiuri S and Pollock C: SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australas Med J. 7:405–415. 2014. View Article : Google Scholar : PubMed/NCBI
9	Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C and Mather A: Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One. 8:e544422013. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Gallagher H and Suckling RJ: Diabetic nephropathy: Where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab. 18:641–647. 2016. View Article : Google Scholar : PubMed/NCBI
12	Penfold SA, Coughlan MT, Patel SK, Srivastava PM, Sourris KC, Steer D, Webster DE, Thomas MC, MacIsaac RJ, Jerums G, et al: Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int. 78:287–295. 2010. View Article : Google Scholar : PubMed/NCBI
13	Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol. 18:621–663. 2000. View Article : Google Scholar : PubMed/NCBI
14	Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D and Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 269:9889–9897. 1994.PubMed/NCBI
15	Morcos M, Sayed AA, Bierhaus A, Yard B, Waldherr R, Merz W, Kloeting I, Schleicher E, Mentz S, Abd el Baki RF, et al: Activation of tubular epithelial cells in diabetic nephropathy. Diabetes. 51:3532–3544. 2002. View Article : Google Scholar : PubMed/NCBI
16	Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, et al: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 371:1392–1406. 2014. View Article : Google Scholar : PubMed/NCBI
17	Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA and Cherney DZ: Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 308:F77–F83. 2015. View Article : Google Scholar : PubMed/NCBI
18	Hovind P, Rossing P, Johnson RJ and Parving HH: Serum uric acid as a new player in the development of diabetic nephropathy. J Ren Nutr. 21:124–127. 2011. View Article : Google Scholar : PubMed/NCBI
19	Satirapoj B, Supasyndh O, Chaiprasert A, Ruangkanchanasetr P, Kanjanakul I, Phulsuksombuti D, Utainam D and Choovichian P: Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population. Nephrology (Carlton). 15:253–258. 2010. View Article : Google Scholar : PubMed/NCBI
20	Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA and Sjöström CD: Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 18:590–597. 2016. View Article : Google Scholar : PubMed/NCBI
21	Inoguchi T and Nawata H: NAD(P)H oxidase activation: A potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets. 6:495–501. 2005. View Article : Google Scholar : PubMed/NCBI
22	Noronha IL, Niemir Z, Stein H and Waldherr R: Cytokines and growth factors in renal disease. Nephrol Dial Transplant. 10:775–786. 1995.PubMed/NCBI
23	Navarro-González JF and Mora-Fernández C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 19:433–442. 2008. View Article : Google Scholar : PubMed/NCBI